Full-Time

Sr. Manager of Market Access

East

Posted on 8/23/2024

Ceribell

Ceribell

201-500 employees

Develops EEG devices for brain activity monitoring

Compensation Overview

$170k - $175k/yr

+ Bonus + Equity

Remote in USA

Remote position in the East region with estimated travel of 25% - 50%.

Remote position in the East region with estimated travel of 25% - 50%.

Remote position in the East region with estimated travel of 25% - 50%.

Category
🩺Medical, Clinical & Veterinary (1)
Required Skills
Sales
Communications
Marketing
Data Analysis
Requirements
  • Bachelor's degree in healthcare administration, business, or related field. Advanced degree preferred.
  • Minimum of 3-5 years of experience in healthcare reimbursement, preferably with inpatient medical devices.
  • Minimum of 2-3 years of experience with hospital coding, billing, or revenue cycle.
  • In-depth knowledge of billing and coding practices in hospital settings, including a strong understanding of the charge master and UB-04 claim forms.
  • Familiarity with reimbursement mechanisms, such as NTAP, and experience navigating the complexities of reimbursement processes.
  • Excellent analytical skills, with the ability to interpret and communicate complex healthcare data to diverse audiences.
  • Strong interpersonal and communication skills, enabling effective collaboration with internal and external stakeholders.
  • Demonstrated ability to work independently and prioritize tasks in a fast-paced, results-oriented environment.
  • Travel: estimated at 25%-50%
Responsibilities
  • Provide expertise in billing and coding practices specific to hospitals.
  • Demonstrate a thorough understanding of the charge master and UB-04 claim forms, ensuring accurate and timely reimbursement for our customers.
  • Work closely with the sales team to support reimbursement efforts and facilitate the successful adoption of our products in various inpatient healthcare settings.
  • Collaborate with the sales team to engage in Health Economics and Outcomes Research activities at accounts.
  • Gather and analyze data related to the cost-effectiveness and value proposition of our products, supporting the sales team in their interactions with key stakeholders.
  • Establish and maintain relationships with key stakeholders such as hospital administrators, reimbursement decision-makers, and insurance companies.
  • Provide educational resources, communicate reimbursement-related updates, and address any concerns or inquiries to ensure a smooth reimbursement process.
  • Ensure adherence to reimbursement regulations, guidelines, and compliance requirements.
  • Stay updated on changing regulatory landscapes and proactively implement necessary measures to maintain compliance with all applicable laws, regulations, and industry standards related to reimbursement practices.
  • Work closely with internal teams, including billing and coding specialists, to analyze and address claims denials.
  • Identify root causes of denials, implement corrective actions, and provide guidance on improving documentation, coding accuracy, and claim submission processes to minimize denials and optimize reimbursement.
  • Foster strong collaboration and communication with cross-functional teams, including sales, marketing, clinical, and regulatory affairs.
  • Act as a subject matter expert on reimbursement matters and provide input and guidance during product development, launch planning, and market access strategies to ensure alignment with reimbursement goals and requirements.
  • Utilize reimbursement data, claims data, and other relevant sources to perform data analysis and generate reports on reimbursement trends, payment patterns, and financial outcomes.
  • Present findings and recommendations to internal stakeholders, assisting them in making data-driven decisions to optimize reimbursement strategies.

Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data on brain activity, which is essential for diagnosing and treating neurological conditions, particularly in urgent situations like Nonconvulsive Status Epilepticus (NCSE). Unlike some other medical devices, the Ceribell EEG Recorder does not provide diagnostic conclusions or automated alerts; instead, it serves as a tool for healthcare professionals to collect data for interpretation. Ceribell generates revenue by selling these devices to healthcare providers, and sales are regulated to ensure they are conducted under physician orders.

Company Size

201-500

Company Stage

Series C

Total Funding

$171M

Headquarters

Mountain View, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-powered EEG systems reduce diagnosis time by 50%, aiding rapid treatment.
  • Ceribell's IPO raised $180 million, indicating strong investor interest.
  • The demand for point-of-care diagnostic tools is increasing in hospitals.

What critics are saying

  • Increased competition from emerging EEG technologies may impact Ceribell's market share.
  • Potential challenges in scaling production due to supply chain constraints.
  • Recent earnings report missing estimates could affect investor confidence.

What makes Ceribell unique

  • Ceribell's EEG system is FDA cleared and requires no specialist interpreter.
  • The Brain Stethoscope converts brainwaves to sound for easy seizure detection.
  • Ceribell's EEG setup takes only 6 minutes, enhancing time-critical treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Holidays

Parental Leave

Annual Bonus Opportunity

Company Equity

Phone/Internet Stipend

Growth & Insights and Company News

Headcount

6 month growth

↑ 1%

1 year growth

↑ 1%

2 year growth

↑ 4%
GlobeNewswire
May 20th, 2025
Ceribell To Participate In The William Blair 45Th Annual Growth Stock Conference

SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m

MarketBeat
May 11th, 2025
Barclays PLC Makes New Investment in CeriBell (NASDAQ:CBLL)

Barclays PLC makes new Investment in CeriBell (NASDAQ:CBLL).

Zolmax
Apr 8th, 2025
CeriBell's $180M Lock-Up Expires Tomorrow

CeriBell's (NASDAQ:CBLL) lock-up period ends on April 9th, allowing major shareholders and insiders to trade shares. The company issued 10,606,060 shares in its IPO on October 11th, raising $180 million at $17 per share. Analysts have given CBLL a consensus "Buy" rating with a $32.50 price target. The stock opened at $18.19, with a 52-week range of $17.24 to $32.75. Recent earnings missed estimates, reporting a loss of $0.40 per share on $18.53 million revenue.

BioSpace
Nov 20th, 2024
Ceribell Appoints Kristie Rodenbush As Chief People Officer And Brian Price As Senior Vice President Of Marketing

—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms

Fierce Biotech
Oct 15th, 2024
Ceribell CEO Jane Chao explains why now was the time for its upsized IPO

Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.

INACTIVE